Supplementary Information (SI) for RSC Medicinal Chemistry. This journal is © The Royal Society of Chemistry 2024

Development of coumarin-inspired bifunctional hybrids as a new class of anti-Alzheimer's agents with potent in vivo efficacy

Atamjit Singh^{1,*}, Aman Sharma¹, Karanvir Singh¹, Kirandeep Kaur¹, Pallvi Mohana², Jignesh Prajapati³, Uttam Kaur⁴, Dweipayan Goswami³, Saroj Arora², Renu Chadha⁵, Preet Mohinder Singh Bedi^{1,6*}

¹Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India

²Department of Botanical and Environmental Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India

³Department of Microbiology & Biotechnology, University School of Sciences, Gujrat University, Ahmedabad, Gujrat 380009, India

⁴University School of Business Management, Chandigarh University, Gharuan 140413, India

⁵University Institute of Pharmaceutical Sciences, Punjab University, Chandigarh 160014, India

⁶Drug and Pollution testing Laboratory, Guru Nanak Dev University, Amritsar, Punjab 143005, India

*Corresponding authors:

1. Dr. Atamjit Singh

Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India

Email id: atampanesar@gmail.com, atamjitpharma.rsh@gndu.ac.in

ORCID: 0000-0001-5439-8032

2. Prof. Preet Mohinder Singh Bedi

Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab 143005, India

Email id: bedi_preet@yahoo.com, preet.pharma@gndu.ac.in

Compound	Ligand Interactions	Dock	Binding energy (\(\Delta G)\)
		score	Kj/mol
AS1	PHE295 TR283 TR283 TR283 TR283 TR283 TR285	-25.8367	-12
AS2	TYR337 PHE388 HIS447 TRP86 TRP86 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL294 UAL2	-29.8742	-2

Table 1. Protein-ligand interactions, dock scores, and binding energy (ΔG) of hybrid molecules.

AS3	TYR341	-22.9106	4
	TYR337 DHE388 HIS447 TRP88 TRP88 CEV121 CLY122 PHE297 LEU289		
AS4		-25.3112	-4
	SER293 VALA PHE295 PHE33 HIS447 TVP341 SER294 LEU200 GLY122 GLY122 GLY122 TRP86		





AS11	PHE338	-26.3132	-7
	TR341 HIS447 HIS447 HIS447 HIS447 HIS447 HIS447 HIS447 HIS447 HIS447 HIS447		
AS12	ER293 Har 94 Trp266 Trp266 Trp266	-22.0890	-12
AS13	TVR 124 TVR 12	-25.4282	4

AS14	1	-21.3793	-22
	SER293 VAL294 PTE339 TYR337 TC2041 PTE339 TYR337 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU202 CLU		
A815	TRP286	-21.6765	-57
Donepezil	TRP86 ASP74 TRP286 TRP286 TRP286 SER293	-28.7716	-43

Compound	mi log P	TPSA ((Ų)	MW (g/mol)	nON	nOHNH
AS1	3.84	88.63	433.46	8	0
AS2	4.11	88.63	447.49	8	0
AS3	4.38	88.63	461.52	8	0
AS4	4.89	88.63	475.55	8	0
AS5	5.39	88.63	489.57	8	0
AS6	3.89	88.63	433.46	8	0
AS7	4.16	88.63	447.49	8	0
AS8	4.43	88.63	461.52	8	0
AS9	4.94	88.63	475.55	8	0
AS10	5.44	88.63	489.57	8	0
AS11	4.27	88.63	447.49	8	0
AS12	4.54	88.63	461.52	8	0
AS13	4.81	88.63	475.55	8	0
AS14	5.31	88.63	489.57	8	0
AS15	5.82	88.63	503.60	8	0

 Table 2. Lipinski parameters of hybrid molecules.

Compound	BBB	CYP2D6	CYP3A4	HIA	MDCK	PPB
		substrate	substrate			
AS1	0.2779	Non	Substrate	98.84	25.7343	90.50
AS2	0.7409	Non	Substrate	98.67	0.2277	92.72
AS3	0.6422	Non	Substrate	98.50	0.7565	90.95
AS4	0.0917	Non	Substrate	98.33	0.3145	91.02
AS5	0.0171	Non	Substrate	98.17	18.8922	91.31
AS6	0.8983	Non	Substrate	98.84	6.3194	91.63
AS7	0.1875	Non	Substrate	98.67	1.8036	93.53
AS8	0.0224	Non	Substrate	98.50	2.7041	91.52
AS9	0.2168	Non	Substrate	98.33	5.2719	91.40
AS10	0.0369	Non	Substrate	98.17	36.2571	91.52
AS11	1.0996	Non	Substrate	98.67	9.7944	91.33
AS12	0.0406	Non	Substrate	98.50	0.6764	93.09
AS13	0.0237	Non	Substrate	98.33	11.1126	91.32
AS14	0.1722	Non	Substrate	98.17	8.3560	91.23
AS15	0.0453	Non	Substrate	98.02	41.4197	91.32

Table 3. ADME properties of hybrid molecules.